Showing results (41-50 of 126) with videos related to
Sort By:
Pageof 13
Blood Advances|August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemiaBrian Ball, Rami S Komrokji, Lionel Adès, et al.Oncotarget|March 31, 2016
Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell deathAlix Dubois, Clemence Ginet, Nathan Furstoss, et al.Oncotarget|September 30, 2015
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromesKathy L McGraw, Thomas Cluzeau, David A Sallman, et al.Annals of Hematology|December 10, 2025
Predicting the toxicity-efficacy ratio of venetoclax in real-world patientsLoïc Osanno, Lucy Brocque, Laurent Bourguignon, et al.Cell Cycle (Georgetown, Tex.)|June 10, 2011
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemiaSylvain Thépot, Elodie Lainey, Thomas Cluzeau, et al.Blood Advances|December 22, 2020
Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseasesGiancarlo Fatobene, Fernanda Volt, Frederico Moreira, et al.Haematologica|March 10, 2022
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALLAurelie Cabannes-Hamy, Eolia Brissot, Thibaut Leguay, et al.Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.Journal of Molecular Cell Biology|April 3, 2012
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressivenessAlexandre Puissant, Maeva Dufies, Nina Fenouille, et al.Transfusion|April 22, 2022
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM)Claire Jouzier, Amina Cherait, Pascale Cony-Makhoul, et al.Pageof 13